⌘K
t
CelLBxHealth plc announced on 30 April 2026 that it will provide a trading update for Q1 2026. The company stated this update is scheduled for release in mid-May.
| Date | 30 Apr 2026 |
| Time | 07:00:10 |
| Category | Miscellaneous |
| ID | 4838C |
CelLBxHealth plc
("CelLBxHealth" or "the Company")
Confirmation of Q1 trading update
Guildford, UK and Plymouth Meeting, U.S. - 30 April 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology, announces that it will provide a trading update for Q1 2026 in mid-May.
For further information:
|
CelLBxHealth plc Peter Collins, Chief Executive Officer Jan Groen, Executive Chairman |
via Walbrook PR |
|
|
|
|
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales) |
+44 (0)20 7220 0500
|
|
|
|
|
Walbrook PR (Investor and Media Relations) Paul McManus / Alice Woodings |
Tel: +44 (0)20 7933 8780 or [email protected] Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
About CelLBxHealth plc
CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial focus span three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.
For more information, visit https://cellbxhealth.com/.